Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02952820 · ClinicalTrials.gov registry record · Phase 3
Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)
A Phase 3 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 3
- Development phase
- 971
- Enrollment target
NCT02952820 is a Phase 3 study that has completed, run by Eisai. The registered enrollment target is 971 participants.
The verdict
NCT02952820, a Phase 3 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 971 participants
- Enrollment target
Study Summary
The key objectives of this study are to determine, using sleep diaries, whether lemborexant at the doses 5 milligrams (mg) and 10 mg is superior to placebo on subjective sleep onset, subjective sleep efficiency, and subjective sleep maintenance in participants with insomnia disorder.
Interventions
- DRUG Placebo
- DRUG lemborexant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 971 participants |
| Start Date | 2016-11-15 |
| Est. Completion | 2019-01-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02952820
The ClinicalTrials.gov registry entry for NCT02952820 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 971 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02952820 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02952820 about?
NCT02952820 is a clinical study titled "Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)". The key objectives of this study are to determine, using sleep diaries, whether lemborexant at the doses 5 milligrams (mg) and 10 mg is superior to placebo on subjective sleep onset, subjective sleep efficiency, and subjective sleep maintenance in participants with insomnia disorder.
What is the current status of trial NCT02952820?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 971 participants. The study started on 2016-11-15. Estimated completion is 2019-01-08.
What interventions are being tested in trial NCT02952820?
The interventions under investigation include: Placebo (DRUG), lemborexant (DRUG).
Who is sponsoring clinical trial NCT02952820?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.